CYPHER® sirolimus-eluting stent (Cordis Corporation, FL, USA) and TAXUS® polymer-based paclitaxel-eluting stent (Boston Scientific Corp., Natick, Massachusetts) are the two drug-eluting stents (DESs) approved by the US Food and Drug Administration for clinical use [1,2]. A number of clinical trials comparing the short-term efficacy of these two DESs have been published recently [3–6]. In essence, the results either showed superiority of the CYPHER stent or equivalence of the two, depending on the population and end-points studied. However, data comparing the long-term clinical outcomes of the two DESs, especially in bifurcation lesions, are limited. We previously reported similar procedural success rates and 30-day clinical outcomes between the two DESs in native de novo bifurcation lesions, but with subacute stent thrombosis occurring only in the TAXUS group [7]. In this report, we sought to present the long-term (N2 years) clinical outcomes of the same patient cohort.